We are live on ! Find out more
EFTR

eFFECTOR Therapeutics, Inc. Common Stock
EFTR

Delisted

EFTR was delisted on the 2nd of July, 2024.

Back to rankings

30 hedge funds and large institutions have $10.4M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

11% more funds holding

Funds holding: 27 → 30 (+3)

24% less capital invested

Capital invested by funds: $13.6M → $10.4M (-$3.22M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.48%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
4
Increased
6
Reduced
2
Closed
1
Calls
$43K
Puts
–
Net Calls
+$43K
Net Calls Change
-$14K

Top Buyers

Rank Fund Capital Flow
1
IDA
Intelligence Driven Advisers
California
+$24.8K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$17.1K
3
Renaissance Technologies
Renaissance Technologies
New York
+$12.4K
4
UBS Group
UBS Group
Switzerland
+$4.94K
5
TRCT
Tower Research Capital (TRC)
New York
+$3.21K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$9K
2
WFAG
Wescott Financial Advisory Group
Pennsylvania
-$7.61K
3
Two Sigma Investments
Two Sigma Investments
New York
-$4.39K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$2.93M – – –
A
2
Abingworth
United Kingdom
$2.06M – – –
CG
3
Column Group
California
$1.84M – – –
SAM
4
Sectoral Asset Management
Quebec, Canada
$1.02M – – –
PA
5
Parallel Advisors
California
$724K – – –
Blackstone Inc
6
Blackstone Inc
New York
$560K – – –
OMC
7
OUP Management Company
Pennsylvania
$439K – – –
ECM
8
Evolution Capital Management
Nevada
$226K – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$183K – – –
Corient Private Wealth
10
Corient Private Wealth
Florida
$118K +$140K +11,018 New
Renaissance Technologies
11
Renaissance Technologies
New York
$94K +$12.4K +980 +13%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$45K – – –
IDA
13
Intelligence Driven Advisers
California
$24.4K +$24.8K +1,951 New
WFAG
14
Wescott Financial Advisory Group
Pennsylvania
$17.3K -$7.61K -600 -27%
Two Sigma Investments
15
Two Sigma Investments
New York
$16.5K -$4.39K -346 -18%
BlackRock
16
BlackRock
New York
$14.9K +$1.41K +111 +9%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$14.4K +$17.1K +1,345 New
RF
18
Resolute Financial
Massachusetts
$13.3K – – –
UBS Group
19
UBS Group
Switzerland
$11.3K +$4.94K +389 +59%
Northern Trust
20
Northern Trust
Illinois
$11.1K – – –
TRCT
21
Tower Research Capital (TRC)
New York
$10K +$3.21K +253 +39%
Millennium Management
22
Millennium Management
New York
$9K +$2.56K +202 +31%
State Street
23
State Street
Massachusetts
$8.59K – – –
MOS
24
MGO One Seven
Ohio
$8.58K – – –
CC
25
Callan Capital
California
$8.55K – – –
1
2

EFTR Hedge Fund Activity: Q4 2022 in Review

30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q4 2022, worth a combined $10.4M — down 24% from $13.6M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new EFTR positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Intelligence Driven Advisers, opening a new position worth an estimated $24.8K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $9K sold.

  • 30 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q4 2022, up from 27 in Q3 2022.
  • Funds reported $10.4M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q4 2022, down 24% quarter-over-quarter.
  • 4 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q4 2022 and 1 closed out, a net change of +3 holders.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q4 2022 was Intelligence Driven Advisers, an estimated $24.8K added.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q4 2022 was Two Sigma Securities, an estimated $9K sold.

Based on aggregated 13F filings for Q4 2022.